AngioDynamics (NASDAQ:ANGO) Issues FY 2026 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of -0.330–0.230 for the period, compared to the consensus earnings per share estimate of -0.310. The company issued revenue guidance of $312.0 million-$314.0 million, compared to the consensus revenue estimate of $310.1 million.

Analysts Set New Price Targets

A number of brokerages have weighed in on ANGO. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Canaccord Genuity Group boosted their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

AngioDynamics Stock Down 13.5%

NASDAQ ANGO opened at $11.44 on Wednesday. The firm’s 50 day moving average is $12.67 and its 200-day moving average is $11.01. The company has a market capitalization of $471.33 million, a PE ratio of -14.67 and a beta of 0.47. AngioDynamics has a 12-month low of $8.27 and a 12-month high of $13.99.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, January 6th. The medical instruments supplier reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.05). The business had revenue of $79.43 million for the quarter, compared to analyst estimates of $76.43 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) EPS. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, sell-side analysts expect that AngioDynamics will post -0.37 EPS for the current year.

Insider Transactions at AngioDynamics

In related news, SVP Lawrence T. Weiss acquired 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 21st. The stock was bought at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the acquisition, the senior vice president directly owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James C. Clemmer bought 10,000 shares of the stock in a transaction that occurred on Thursday, October 9th. The stock was bought at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the transaction, the chief executive officer owned 882,529 shares of the company’s stock, valued at $9,840,198.35. The trade was a 1.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 20,890 shares of company stock valued at $239,532. Company insiders own 6.00% of the company’s stock.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Q2 revenue beat and growth — Revenue was ~$79.4M, up ~9% year-over-year and above consensus; management highlighted continued double‑digit med‑tech growth. Read More.
• Positive Sentiment: Raised revenue guidance and cash‑flow outlook — FY‑2026 revenue guide was raised to $312–$314M (vs. consensus ~$310M) and the company says it still expects to be cash‑flow positive for FY26. Read More.
• Positive Sentiment: Insider buying and analyst interest — Recent insider purchases and several buy ratings/price targets remain on file, a signal of confidence from insiders and some sell‑side firms. Read More.
• Neutral Sentiment: Improving cash generation but mixed balance sheet moves — Operating cash flow improved materially (reported ~ $4.7M), and liabilities declined, though cash on hand is down year‑over‑year. These operational improvements reduce execution risk but don’t eliminate near‑term losses. Read More.
• Negative Sentiment: EPS miss and continued unprofitability — GAAP diluted loss per share was $0.15 vs. the expected $0.10 loss; the company remains unprofitable with negative margins, which keeps valuation sensitive to execution. Read More.
• Negative Sentiment: Leadership uncertainty — An unexpected senior executive departure reported alongside the quarter is amplifying investor concern and helping explain the share weakness despite the operational beats. Read More.

Institutional Investors Weigh In On AngioDynamics

Several large investors have recently made changes to their positions in the stock. UBS Group AG lifted its stake in AngioDynamics by 83.6% in the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after acquiring an additional 501,881 shares during the last quarter. Millennium Management LLC raised its holdings in shares of AngioDynamics by 28.1% in the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after purchasing an additional 393,682 shares during the period. Bank of America Corp DE lifted its stake in AngioDynamics by 729.4% in the 2nd quarter. Bank of America Corp DE now owns 286,208 shares of the medical instruments supplier’s stock valued at $2,839,000 after purchasing an additional 251,702 shares during the last quarter. Moore Capital Management LP lifted its stake in AngioDynamics by 162.5% in the 3rd quarter. Moore Capital Management LP now owns 237,964 shares of the medical instruments supplier’s stock valued at $2,658,000 after purchasing an additional 147,324 shares during the last quarter. Finally, Armistice Capital LLC grew its holdings in AngioDynamics by 7.1% during the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the medical instruments supplier’s stock worth $18,274,000 after purchasing an additional 108,185 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.